Evidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 2 of the 28 sources its claims cite were checked for support.
Abstract
In Plasmodium falciparum-endemic areas, pregnancy-associated malaria (PAM) is an important health problem. The condition is precipitated by accumulation of parasite-infected erythrocytes (IEs) in the placenta, and this process is mediated by parasite-encoded variant surface antigens (VSA) binding to chondroitin sulfate A (CSA). Parasites causing PAM express unique VSA types, VSAPAM, which can be serologically classified as sex specific and parity dependent. It is sex specific because men from malaria-endemic areas do not develop VSAPAM antibodies; it is parity dependent because women acquire anti-VSAPAM immunoglobulin (Ig) G as a function of parity. Previously, it was shown that transcription of var2csa is up-regulated in placental parasites and parasites selected for CSA binding. Here, we show the following: (a) that VAR2CSA is expressed on the surface of CSA-selected IEs; (b) that VAR2CSA is recognized by endemic plasma in a sex-specific and parity-dependent manner; (c) that high anti-VAR2CSA IgG levels can be found in pregnant women from both West and East Africa; and (d) that women with high plasma levels of anti-VAR2CSA IgG give birth to markedly heavier babies and have a much lower risk of delivering low birth weight children than women with low levels.
Overview
CoChat Summary
TL;DR
This study provides evidence that VAR2CSA is expressed on the surface of CSA-selected *Plasmodium falciparum*–infected erythrocytes and is recognized by plasma IgG in a sex-specific and parity-dependent manner characteristic of pregnancy-associated malaria. High anti-VAR2CSA IgG levels were associated with markedly heavier babies and lower risk of low birth weight in women with active-chronic placental infection.
Key findings
- Rabbit antisera against VAR2CSA DBL5-ε and DBL1-X labeled the surface of CSA-selected, VSAPAM-expressing parasite lines by flow cytometry and confocal microscopy, but did not label isogenic lines not expressing VSAPAM.
- VAR2CSA-specific IgG levels were higher in women than men: for DBL5-ε, median difference [95% CI] was 0.14 [0.081–0.27] in one Ghanaian panel and 2.34 [1.46–2.59] in a separate term-pregnant-women/men panel; both P < 0.001. Levels also correlated with parity (rs = 0.38, P = 0.0027; P = 0.03 in a model including parity and age).
- Among 110 Kenyan women with histological active-chronic placental *P. falciparum* infection, high above-median VAR2CSA DBL5-ε IgG was associated with a fourfold lower risk of low birth weight (<2.500 g): odds ratio 0.25 [95% CI 0.10–0.63], P = 0.003.
- Women with high VAR2CSA DBL5-ε IgG delivered babies weighing 2.864 g (95% CI 2.700–3.029 g) versus 2.436 g (95% CI 2.264–2.608 g) for women with low levels.
Methods
- Recombinant VAR2CSA domains DBL1-X and DBL5-ε were produced from a synthetic 3D7 *var2csa* gene; rabbit antisera were raised against these proteins, with VAR4 DBL5-δ and GLURP used as control antigens.
- Plasma panels came from Ghanaian individuals exposed to hyperendemic seasonal or stable *P. falciparum* transmission: 39 men and 46 women; 30 men and 27 term-pregnant women; 62 pregnant women at delivery; plus 110 Kenyan women with active-chronic placental infection and six unexposed negative controls.
- Parasite lines NF54 and FCR3 were selected for CSA adhesion or for VAR2CSA DBL5-ε IgG binding; surface reactivity was assessed by flow cytometry and confocal microscopy, antibody levels by ELISA, and associations by Mann-Whitney, Spearman correlation, and logistic regression.
Limitations
- The paper does not state a limitations section. Evident from the text: the birth-weight analysis is observational and restricted to 110 Kenyan women with active-chronic placental infection, so causality and broader generalizability are not established.
- Evident from the text: CSA-selected NF54 showed a double peak, with only approximately half the parasites expressing VAR2CSA, requiring additional antibody-based selection; this indicates heterogeneity in VAR2CSA expression among CSA-selected parasites.
- Evident from the text: the study demonstrates surface expression and serological association but does not directly show that VAR2CSA itself mediates CSA binding or that anti-VAR2CSA IgG blocks placental adhesion.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
2 Valid · 0 Not valid · 13 Not checked · 31 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, sex-specific and parity-dependent plasma IgG recognition of IEs after Saimiri brain endothelial cell selection has not been reported, but domains from VAR1CSA do not show the expected VSAPAM-type sex-specific and parity-dependent IgG recognition (30).”
§ Evidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria > Results and Discussion
What the sources say
- Supportedcites [30] 2003, Infect. Immun. source
The citation (30) is attached to the second clause, and our copy of Jensen et al. (2003) states exactly that: the abstract reports that 'antibody recognition of recombinant products of a specific VSA gene (2O2var1) implicated in PAM ... did not have these characteristics', and the Results (Fig. 2 discussion) state 'in no case was there any significant difference in reactivity between plasma samples from malaria-exposed males and females, and there was no evidence of parity dependency of any of the domain-specific antibody reactivities (P > 0.05)', against gender-specific and parity-dependent recognition of native VSAPAM on 2O2-CSA (Fig. 1). The paper designates the gene 2O2var1 (a var1-type/CSA-implicated gene) rather than 'VAR1CSA', a nomenclature difference only. The first clause — that sex-specific/parity-dependent IgG recognition after Saimiri brain endothelial cell selection has not been reported — is not carried by this citation and is not addressed in our copy, which used CSA-adherence selection (2O2-CSA) rather than Saimiri selection. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, GLURP-specific IgG levels did not depend significantly on parity (P = 0.94; unpublished data).”
§ Evidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria > Results and Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The double peak in the flow diagram of anti-VAR2CSA–labeled CSA-selected NF54 (Figs. 1 a and 2 a) indicated that approximately half of these parasites expressed VAR2CSA”
§ Evidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria > Results and Discussion
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Here, we show that 3D7 VAR2CSA-specific antisera labeled different CSA-selected parasite lines (Fig. 1)”
§ Evidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria > Results and Discussion
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Logistic regression analysis showed that high (i.e., above median) plasma levels of VAR2CSA DBL5-ɛ–specific plasma IgG were associated with a fourfold lower risk of giving birth to a seriously underweight (<2.500 g) infant (Table I).”
- Also stated in: § Results and Discussion · plain
“VAR2CSA DBL5-ɛ IgG > median | 0.25 [0.10–0.63] | 0.003”
§ Evidence for the Involvement of VAR2CSA in Pregnancy-associated Malaria > Results and Discussion
plainstates an associationn = 110- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results and Discussion · plain
24 more claims
Create a free account to see all 46 claims and to verify the 3 references still open.
- Probably not a substantial claim. 7
- It may state two separate claims as one. 11
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“VAR2CSA is preferentially expressed by placental parasites and isolates selected to bind CSA [14,15], and is currently the leading candidate for a vaccine to prevent malaria during pregnancy.”
From Designing a VAR2CSA-based vaccine to prevent placental malaria (2015) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The binding of the variant surface antigen (VAR2CSA) with chondroitin sulphate A has been implicated in the pathology of falciparum malaria in pregnancy.65–68”
From Malaria in pregnancy. (2013) · cites this paper as [65]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Levels of anti-VAR2CSA specific IgGs increase with parity, cannot be found in men and are associated with a favourable pregnancy outcome 64–66 so that the malaria risk decreases with increasing parity.”
From Malaria in pregnancy. (2013) · cites this paper as [65]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Infected erythrocyte (IE) adhesion to CSA is mediated by VAR2CSA, a member of the P. falciparum erythrocyte membrane protein family (PfEMP1) that is preferentially expressed by placental parasites and parasites selected to bind CSA [3–5].”
From Antibody levels to recombinant VAR2CSA domains vary with Plasmodium falciparum parasitaemia, gestational age, and gravidity, but do not predict pregnancy outcomes (2018) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Levels of anti-DBL5ε IgG have also been positively associated with birth weight, again indicating their protective effect [6].”
From Differential recognition of P. falciparum VAR2CSA domains by naturally acquired antibodies in pregnant women from a malaria endemic area (2010) · cites this paper as [6]
Citations
Cites
Genome sequence of the human malaria parasite Plasmodium falciparum
Gardner, M. J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R. W., Carlton, J. M., Pain, A., Nelson, K. E., Bowman, S., et al. (2002) · Nature · doi:10.1038/nature01097 · Cited by 4,407
Su, X.-Z., Heatwole, V. M., Wertheimer, S. P., Guinet, F., Herrfeldt, J. A., Peterson, D. S., Ravetch, J. A., & Wellems, T. E. (1995) · Cell · doi:10.1016/0092-8674(95)90055-1 · Cited by 1,219
Adherence of Plasmodium falciparum to Chondroitin Sulfate A in the Human Placenta
Fried, M., & Duffy, P. E. (1996) · Science · doi:10.1126/science.272.5267.1502 · Cited by 1,108
Pushing the limits of the scanning mechanism for initiation of translation
Kozak, M. (2002) · Gene · doi:10.1016/s0378-1119(02)01056-9 · Cited by 919
An analysis of malaria in pregnancy in Africa.
Brabin, B. J. (1983) · PubMed · Cited by 782
Salanti, A., Staalsoe, T., Lavstsen, T., Jensen, A. T. R., Sowa, M. P. K., Arnot, D. E., Hviid, L., & Theander, T. G. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03570.x · Cited by 702
Self-citationMaternal antibodies block malaria
Fried, M., Nosten, F., Brockman, A., Brabin, B. J., & Duffy, P. E. (1998) · Nature · doi:10.1038/27570 · Cited by 659
Lavstsen, T., Salanti, A., Jensen, A. T., Arnot, D. E., & Theander, T. G. (2003) · Malaria Journal · doi:10.1186/1475-2875-2-27 · Cited by 347
Self-citationJensen, A. T. R., Magistrado, P., Sharp, S., Joergensen, L., Lavstsen, T., Chiucchiuini, A., Salanti, A., Vestergaard, L. S., Lusingu, J. P., Hermsen, R., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040274 · Cited by 322
Self-citationRicke, C. H., Staalsoe, T., Koram, K., Akanmori, B. D., Riley, E. M., Theander, T. G., & Hviid, L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.6.3309 · Cited by 303
Self-citation
Research works printed but not linked: 1
- 1983, Bull. World Health Organ., 61, 1005
Cited by
Items 101–140 of 140
Francis, S. E., Malkov, V. A., Oleinikov, A. V., Rossnagle, E., Wendler, J. P., Mutabingwa, T. K., Fried, M., & Duffy, P. E. (2007) · Infection and Immunity · doi:10.1128/iai.00635-07 · Cited by 65
Bigey, P., Gnidehou, S., Doritchamou, J., Quiviger, M., Viwami, F., Couturier, A., Salanti, A., Nielsen, M. A., Scherman, D., Deloron, P., et al. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir499 · Cited by 63
Self-citationBarfod, L., Dobrilovic, T., Magistrado, P., Khunrae, P., Viwami, F., Bruun, J., Dahlbäck, M., Bernasconi, N. L., Fried, M., John, D., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002390 · Cited by 62
“bly acts by blocking adhesion of IEs to CSA and by opsonizing IEs for phagocytosis (3, 9, 10).”
BackgroundSelf-citationThe distinct proteome of placental malaria parasites
Fried, M., Hixson, K. K., Anderson, L., Ogata, Y., Mutabingwa, T. K., & Duffy, P. E. (2007) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2007.05.010 · Cited by 61
Characterization of anti-var2CSA-PfEMP1 cytoadhesion inhibitory mouse monoclonal antibodies
Avril, M., Gamain, B., Lépolard, C., Viaud, N., Scherf, A., & Gysin, J. (2006) · Microbes and Infection · doi:10.1016/j.micinf.2006.09.005 · Cited by 61
VAR2CSA Expression on the Surface of Placenta‐Derived Plasmodium falciparum–Infected Erythrocytes
Magistrado, P., Salanti, A., Tuikue Ndam, N. G., Mwakalinga, S. B., Resende, M., Dahlbäck, M., Hviid, L., Lusingu, J., Theander, T. G., & Nielsen, M. A. (2008) · The Journal of Infectious Diseases · doi:10.1086/591502 · Cited by 61
Self-citationOleinikov, A. V., Rossnagle, E., Francis, S., Mutabingwa, T. K., Fried, M., & Duffy, P. E. (2007) · The Journal of Infectious Diseases · doi:10.1086/518513 · Cited by 59
“in Escherichia coli [33] and with varying numbers of VAR2CSA domains (2 [25], 3 [26], or 6 [27]) expressed in the baculovirus”
BackgroundInfluentialImmunologic activation of human syncytiotrophoblast by Plasmodium falciparum
Lucchi, N. W., Peterson, D. S., & Moore, J. M. (2008) · Malaria Journal · doi:10.1186/1475-2875-7-42 · Cited by 58
“The most well characterized PfEMP1 variant identified to mediate iRBC binding to the placenta is VAR2CSA [ 23- 25 ].”
BackgroundWang, K., Dagil, R., Lavstsen, T., Misra, S. K., Spliid, C. B., Wang, Y., Gustavsson, T., Sandoval, D. R., Vidal-Calvo, E. E., Choudhary, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23254-1 · Cited by 52
Self-citationBenavente, E. D., Oresegun, D. R., de Sessions, P. F., Walker, E. M., Roper, C., Dombrowski, J. G., de Souza, R. M., Marinho, C. R. F., Sutherland, C. J., Hibberd, M. L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33767-3 · Cited by 47
Bir, N., Yazdani, S. S., Avril, M., Layez, C., Gysin, J., & Chitnis, C. E. (2006) · Infection and Immunity · doi:10.1128/iai.00481-06 · Cited by 49
Plasmodium falciparum transcriptome analysis reveals pregnancy malaria associated gene expression
Tuikue Ndam, N., Bischoff, E., Proux, C., Lavstsen, T., Salanti, A., Guitard, J., Nielsen, M. A., Coppée, J.-Y., Gaye, A., Theander, T., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001855 · Cited by 48
Self-citationMagistrado, P. A., Minja, D., Doritchamou, J., Tuikue Ndam, N., John, D., Schmiegelow, C., Massougbodji, A., Dahlbäck, M., Ditlev, S. B., Pinto, V. V., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.10.080 · Cited by 49
Self-citationSeveral domains from VAR2CSA can induce Plasmodium falciparum adhesion-blocking antibodies
Salanti, A., Resende, M., Ditlev, S. B., Pinto, V. V., Dahlbäck, M., Andersen, G., Manczak, T., Theander, T. G., & Nielsen, M. A. (2010) · Malaria Journal · doi:10.1186/1475-2875-9-11 · Cited by 42
“Likewise, high anti-VAR2CSA IgG levels are correlated with protection against the clinical consequences of PAM [13].”
InfluentialSelf-citationDechavanne, C., Cottrell, G., Garcia, A., & Migot-Nabias, F. (2015) · PLOS ONE · doi:10.1371/journal.pone.0145464 · Cited by 42
Avril, M., Hathaway, M. J., Srivastava, A., Dechavanne, S., Hommel, M., Beeson, J. G., Smith, J. D., & Gamain, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016622 · Cited by 40
“Furthermore, VAR2CSA appears to be a major target of the antibody mediated immune response in pregnant women [15,20], and parasites in which var2csa is genetically disrupted largely lose the ability to bind to CSA [12,17] and placental syncytiotrophoblast [21], suggesting it is the primary var gene responsible for pla…”
BackgroundMinja, D. T., Schmiegelow, C., Oesterholt, M., Magistrado, P. A., Boström, S., John, D., Pehrson, C., Andersen, D., Deloron, P., Salanti, A., et al. (2012) · Malaria Journal · doi:10.1186/1475-2875-11-211 · Cited by 37
“falciparum erythrocyte membrane protein 1 (PfEMP-1) family expressed on the surface of infected erythrocytes (IEs) mediates sequestration of IEs in the intervillous spaces of the placenta by binding to chondroitin sulphate A (CSA) receptors [10,11].”
BackgroundSelf-citationResende, M., Nielsen, M. A., Dahlbäck, M., Ditlev, S. B., Andersen, P., Sander, A. F., Ndam, N. T., Theander, T. G., & Salanti, A. (2008) · Malaria Journal · doi:10.1186/1475-2875-7-104 · Cited by 36
“High levels of anti-VAR2CSA antibodies are correlated with favourable birth outcome and they are acquired as a function of parity [ 22 ].”
BackgroundSelf-citationGnidehou, S., Doritchamou, J., Arango, E. M., Cabrera, A., Arroyo, M. I., Kain, K. C., Ndam, N. T., Maestre, A., & Yanow, S. K. (2014) · Infection and Immunity · doi:10.1128/iai.01594-14 · Cited by 34
Nielsen, M. A., Resende, M., Alifrangis, M., Turner, L., Hviid, L., Theander, T. G., & Salanti, A. (2007) · Experimental Parasitology · doi:10.1016/j.exppara.2007.03.002 · Cited by 33
“It is furthermore consistent the finding that the VAR2CSA antigen is recognised only by antibodies from past infected and pregnant females (Salanti et al., 2004).”
BackgroundResultSelf-citationFried, M., Kurtis, J. D., Swihart, B., Morrison, R., Pond-Tor, S., Barry, A., Sidibe, Y., Keita, S., Mahamar, A., Andemel, N., et al. (2018) · Malaria Journal · doi:10.1186/s12936-018-2258-9 · Cited by 30
Utilizing nanobody technology to target non-immunodominant domains of VAR2CSA
Ditlev, S. B., Florea, R., Nielsen, M. A., Theander, T. G., Magez, S., Boeuf, P., & Salanti, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084981 · Cited by 31
“During subsequent pregnancies, women build up protective immunity to placental malaria by acquiring antiVAR2CSA antibodies that prevent IE binding to CSA in the placenta [6,7].”
Self-citationDoritchamou, J., Bigey, P., Nielsen, M. A., Gnidehou, S., Ezinmegnon, S., Burgain, A., Massougbodji, A., Deloron, P., Salanti, A., & Ndam, N. T. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.072 · Cited by 29
Self-citationBabakhanyan, A., Leke, R. G. F., Salanti, A., Bobbili, N., Gwanmesia, P., Leke, R. J. I., Quakyi, I. A., Chen, J. J., & Taylor, D. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088173 · Cited by 26
Self-citationGowda, A. S. P., Madhunapantula, S. V., Achur, R. N., Valiyaveettil, M., Bhavanandan, V. P., & Gowda, D. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m604741200 · Cited by 26
Brolin, K. J. M., Persson, K. E. M., Wahlgren, M., Rogerson, S. J., & Chen, Q. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009230 · Cited by 24
“DBL5e also displays a parity dependent recognition, as previously described for VSA-PAM antibodies [34,35] suggesting this domain to be important in a protective response against PAM (figure 1E).”
BackgroundMlugu, E. M., Minzi, O., Asghar, M., Färnert, A., Kamuhabwa, A. A. R., & Aklillu, E. (2020) · Pathogens · doi:10.3390/pathogens9030207 · Cited by 25
Decreasing Malaria Prevalence and Its Potential Consequences for Immunity in Pregnant Women
Teo, A., Hasang, W., Randall, L. M., Feng, G., Bell, L., Unger, H., Langer, C., Beeson, J. G., Siba, P. M., Mueller, I., et al. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu264 · Cited by 25
Requena, P., Rui, E., Padilla, N., Martínez-Espinosa, F. E., Castellanos, M. E., Bôtto-Menezes, C., Malheiro, A., Arévalo-Herrera, M., Kochar, S., Kochar, S. K., et al. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0005009 · Cited by 24
Lopez-Perez, M., Larsen, M. D., Bayarri-Olmos, R., Ampomah, P., Stevenson, L., Arévalo-Herrera, M., Herrera, S., & Hviid, L. (2018) · Infection and Immunity · doi:10.1128/iai.00136-18 · Cited by 24
“pregnant, and the levels generally correlate with parity among such women (18, 19).”
BackgroundSelf-citationCharnaud, S. C., McGready, R., Herten-Crabb, A., Powell, R., Guy, A., Langer, C., Richards, J. S., Gilson, P. R., Chotivanich, K., Tsuboi, T., et al. (2016) · Scientific Reports · doi:10.1038/srep20859 · Cited by 23
Doritchamou, J., Sabbagh, A., Jespersen, J. S., Renard, E., Salanti, A., Nielsen, M. A., Deloron, P., & Tuikue Ndam, N. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137695 · Cited by 22
“VAR2CSA is currently considered as the prime candidate for vaccine development [19] because: (i) VAR2CSA-expressing parasites are the primary cause of PM, (ii) anti-VAR2CSA antibody levels increase with gravidity, as do the levels of antibodies that inhibit IE binding to CSA, (iii) women who have been exposed to PM an…”
BackgroundSelf-citationPinto, V. V., Ditlev, S. B., Jensen, K. E., Resende, M., Dahlbäck, M., Andersen, G., Andersen, P., Theander, T. G., Salanti, A., & Nielsen, M. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017942 · Cited by 18
Self-citationDavies, H., Belda, H., Broncel, M., Dalimot, J., & Treeck, M. (2023) · eLife · doi:10.7554/elife.86367 · Cited by 17
Higgins, M. K. (2008) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309108004211 · Cited by 16
“It is also highly expressed in isolates taken from placental samples, but is not found in isolates from children (Salanti et al., 2003; Tuikue Ndam et al., 2005), and the protein is only detected on the surface of parasites after selection for CSA binding (Salanti et al., 2004; Barfod et al., 2006).”
BackgroundNunes-Silva, S., Gangnard, S., Vidal, M., Vuchelen, A., Dechavanne, S., Chan, S., Pardon, E., Steyaert, J., Ramboarina, S., Chêne, A., et al. (2014) · Scientific Reports · doi:10.1038/srep07373 · Cited by 15
Raghavan, S. S. R., Dagil, R., Lopez-Perez, M., Conrad, J., Bassi, M. R., Quintana, M. D. P., Choudhary, S., Gustavsson, T., Wang, Y., Gourdon, P., et al. (2022) · PLOS Pathogens · doi:10.1371/journal.ppat.1010924 · Cited by 14
Self-citationTowards a vaccine against pregnancy-associated malaria
Tuikue Ndam, N., & Deloron, P. (2008) · Parasite · doi:10.1051/parasite/2008153515 · Cited by 14
Requena, P., Arévalo-Herrera, M., Menegon, M., Martínez-Espinosa, F. E., Padilla, N., Bôtto-Menezes, C., Malheiro, A., Hans, D., Castellanos, M. E., Robinson, L., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00163 · Cited by 13
Iyamu, U., Vinals, D. F., Tornyigah, B., Arango, E., Bhat, R., Adra, T. R., Grewal, S., Martin, K., Maestre, A., Overduin, M., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1202276 · Cited by 7
Metadata
- Authors
- Salanti, A., Dahlbäck, M., Turner, L., Nielsen, M. A., Barfod, L., Magistrado, P., Jensen, A. T. R., Lavstsen, T., Ofori, M. F., Marsh, K., Hviid, L., & Theander, T. G.
- Affiliations
- University of Copenhagen (DK)
- 1Centre for Medical Parasitology, Department of Medical Microbiology and Immunology, University of Copenhagen
- University of Ghana (GH)
- Kenya Medical Research Institute (KE)
- Corresponding author
- Salanti, Ali
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2004-11-01
- Volume
- 200
- Issue
- 9
- Pages
- 1197-1203
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2211857
- OpenAlex
- W2139449809
- Cited by
- 604
- References
- 30
- Citations by year
- 2026: 16 · 2025: 17 · 2024: 23 · 2023: 31 · 2022: 28 · 2021: 32 · 2020: 23 · 2019: 27 · 2018: 25 · 2017: 43 · 2016: 24 · 2015: 32 · 2014: 31 · 2013: 27 · 2012: 26
- FWCI
- 26.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- Sundhed og Sygdom, Det Frie Forskningsråd
- European Commission
- Medical Research Council
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
- Keywords
- malaria in pregnancy, VAR2CSA, Plasmodium falciparum, variant surface antigens, chondroitin sulfate A, placental malaria, low birth weight
- MeSH terms
- Africa, Birth Weight, Chondroitin Sulfates, Enzyme-Linked Immunosorbent Assay, Erythrocytes, Female, Humans, Immunoglobulin G, Male, Placenta, Pregnancy, Recombinant Proteins, Sex Factors, Protozoan Proteins, Malaria, Falciparum, DNA Primers, Microscopy, Confocal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.